Australia markets close in 5 hours 51 minutes

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.4100-0.6600 (-13.02%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.0700
Open4.8600
Bid4.3900 x 1200
Ask5.0100 x 800
Day's range4.4100 - 5.0050
52-week range3.3000 - 7.4500
Volume12,391
Avg. volume20,566
Market cap36.737M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.0240
Earnings date12 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.00
  • Business Wire

    Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

    ATLANTA, May 12, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced financial results for the first quarter ended March 31, 2022.

  • Business Wire

    Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022

    ATLANTA, May 05, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its first quarter 2022 financial results will be reported on Thursday, May 12, 2022 before the open of the financial markets. Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m. ET to discuss the results and provide

  • Business Wire

    Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b "FORTRESS" Clinical Trial for Fibromyalgia

    ATLANTA, April 28, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it has completed enrollment in its Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 ("HSV-1")) study, which is a randomized, double-blind evaluation of IMC-1 in patients with fibr